Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
Balance Sheet
Balance Sheet Decomposition
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Balance Sheet
Shenzhen Chipscreen Biosciences Co Ltd
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
109
|
103
|
131
|
205
|
319
|
600
|
602
|
371
|
375
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
300
|
509
|
371
|
375
|
|
| Cash Equivalents |
109
|
103
|
131
|
205
|
319
|
300
|
93
|
0
|
0
|
|
| Short-Term Investments |
3
|
0
|
41
|
479
|
313
|
82
|
473
|
474
|
478
|
|
| Total Receivables |
8
|
29
|
50
|
82
|
50
|
130
|
168
|
224
|
183
|
|
| Accounts Receivables |
6
|
27
|
46
|
38
|
42
|
111
|
153
|
197
|
161
|
|
| Other Receivables |
2
|
2
|
5
|
43
|
8
|
19
|
15
|
27
|
22
|
|
| Inventory |
4
|
9
|
9
|
11
|
12
|
15
|
28
|
47
|
41
|
|
| Other Current Assets |
103
|
170
|
2
|
296
|
76
|
111
|
6
|
14
|
6
|
|
| Total Current Assets |
226
|
311
|
234
|
1 072
|
769
|
639
|
1 184
|
1 130
|
1 083
|
|
| PP&E Net |
91
|
188
|
283
|
387
|
646
|
816
|
1 115
|
1 072
|
1 167
|
|
| PP&E Gross |
91
|
188
|
283
|
387
|
646
|
816
|
1 115
|
1 072
|
1 167
|
|
| Accumulated Depreciation |
12
|
12
|
14
|
16
|
20
|
34
|
55
|
84
|
110
|
|
| Intangible Assets |
84
|
145
|
181
|
205
|
262
|
356
|
467
|
583
|
601
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
33
|
74
|
389
|
363
|
|
| Other Long-Term Assets |
2
|
12
|
19
|
27
|
50
|
51
|
57
|
30
|
37
|
|
| Total Assets |
403
N/A
|
656
+63%
|
716
+9%
|
1 691
+136%
|
1 726
+2%
|
1 894
+10%
|
2 896
+53%
|
3 203
+11%
|
3 251
+1%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
0
|
4
|
0
|
0
|
4
|
2
|
0
|
9
|
2
|
|
| Accrued Liabilities |
7
|
9
|
17
|
16
|
25
|
45
|
51
|
83
|
87
|
|
| Short-Term Debt |
0
|
10
|
0
|
63
|
35
|
120
|
186
|
130
|
100
|
|
| Current Portion of Long-Term Debt |
2
|
3
|
10
|
0
|
0
|
23
|
23
|
39
|
137
|
|
| Other Current Liabilities |
103
|
51
|
55
|
58
|
83
|
104
|
281
|
129
|
125
|
|
| Total Current Liabilities |
112
|
77
|
82
|
137
|
147
|
294
|
541
|
391
|
451
|
|
| Long-Term Debt |
30
|
65
|
88
|
37
|
23
|
6
|
599
|
909
|
1 096
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
23
|
39
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
60
|
0
|
0
|
|
| Other Liabilities |
48
|
64
|
70
|
71
|
63
|
177
|
180
|
170
|
83
|
|
| Total Liabilities |
190
N/A
|
206
+8%
|
239
+16%
|
245
+2%
|
232
-5%
|
477
+105%
|
1 380
+190%
|
1 493
+8%
|
1 670
+12%
|
|
| Equity | ||||||||||
| Common Stock |
104
|
108
|
360
|
410
|
410
|
411
|
411
|
411
|
408
|
|
| Retained Earnings |
105
|
81
|
36
|
17
|
15
|
37
|
54
|
143
|
28
|
|
| Additional Paid In Capital |
214
|
423
|
153
|
1 053
|
1 069
|
1 125
|
1 075
|
1 138
|
1 013
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
155
|
155
|
113
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
130
|
131
|
132
|
|
| Total Equity |
213
N/A
|
451
+111%
|
477
+6%
|
1 446
+203%
|
1 494
+3%
|
1 418
-5%
|
1 515
+7%
|
1 710
+13%
|
1 581
-8%
|
|
| Total Liabilities & Equity |
403
N/A
|
656
+63%
|
716
+9%
|
1 691
+136%
|
1 726
+2%
|
1 894
+10%
|
2 896
+53%
|
3 203
+11%
|
3 251
+1%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
104
|
108
|
360
|
410
|
410
|
407
|
407
|
408
|
408
|
|